|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development. |
| 公司地址
| 245 First Street, Suite 1400, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 871-2098 |
| 傳真號碼
| +1 617 871-2099 |
| 公司網頁
| https://www.akebia.com |
| 員工數量
| 194 |
| Mr. Richard C. Malabre |
Senior Vice President and Chief Accounting Officer |
-- |
26/02/2026 |
| Mr. John P. Butler |
Director, President and Chief Executive Officer |
美元 864.01K |
28/04/2026 |
| Dr. Steven Keith Burke, M.D. |
Senior Vice President, Chief Research and Development and Chief Medical Officer |
美元 600.54K |
28/04/2026 |
| Mr. Erik John Ostrowski |
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer |
美元 552.92K |
28/04/2026 |
| Ms. Carolyn M. Rucci |
Senior Vice President, Chief Legal Officer and Secretary |
-- |
28/04/2026 |
| Mr. Nicholas Grund |
Senior Vice President and Chief Commercial Officer |
美元 506.74K |
28/04/2026 |
|
|
| Mr. Adrian Adams |
Chairman of the Board |
28/04/2026 |
| Ms. LeAnne M. Zumwalt |
Independent Director |
28/04/2026 |
| Mr. Michael W. Rogers |
Independent Director |
28/04/2026 |
| Ms. Cynthia Smith |
Independent Director |
28/04/2026 |
| Mr. John P. Butler |
Director, President and Chief Executive Officer |
28/04/2026 |
| Dr. Myles Wolf, M.D. |
Independent Director |
28/04/2026 |
| Mr. Ronald E. Frieson |
Independent Director |
28/04/2026 |
| Dr. Philip J. Vickers, PhD |
Director |
01/04/2026 |
|
|
|
|
